Merck KGaA signs $3 billion agreement to develop Parkinson's treatments through AI technology.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2025
0mins
Source: SeekingAlpha
Partnership Announcement: Valo Health has formed a strategic partnership with Germany’s Merck KGaA, valued at up to $3 billion, to develop medicines for Parkinson’s disease using Valo's AI platform.
AI-Driven Drug Discovery: Merck KGaA will utilize Valo’s AI-driven human causal biology platform to identify disease targets and facilitate the delivery of preclinical drugs, enhancing the drug discovery process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
